All In MedTech

Device type · QLT

Covid-19 Multi-Analyte Respiratory Panel Nucleic Acid Devices

FDA groups similar devices under a three-letter product code. This page gathers what FDA's public data says about QLT: how it is classified, what has been cleared or approved, and what has been reported and recalled.

Last checked: Nov 20, 2026Source: openFDAMethods & limitations

How FDA classifies it

Device type
Covid-19 Multi-Analyte Respiratory Panel Nucleic Acid Devices
Product code
QLT
Device class
Not classified
Review panel
Microbiology

Latest FDA decisions

All decisions for QLT

No 510(k), De Novo or PMA decisions for this product code since 2015.

Adverse event reports received per month

By the date FDA received each report, stacked by event type. The newest month is incomplete.

Open in the MAUDE Monitor
  • Malfunction
  • Injury
  • Death
  • Other
View as table
MonthMalfunctionInjuryDeathOther
Dec 2312100
Jan 2428000
Feb 2425000
Mar 2421000
Apr 2429000
May 243000
Jun 241000
Jul 242000
Aug 241100
Sep 242000
Oct 240000
Nov 241000
Dec 241000
Jan 250000
Feb 250000
Mar 251000
Apr 251000
May 250000
Jun 250000
Jul 250000
Aug 250000
Sep 250000
Oct 250000
Nov 250000
Dec 250000
Jan 260000
Feb 260000
Mar 260000
Apr 261000
May 260000
Jun 260000
Jul 260000
Aug 260000
Sep 260000
Oct 260000
Nov 260000

Manufacturers named most often

Last 12 months. Bigger sellers get more reports. This is not a ranking of safety.

Device problems as coded

Last 12 months. FDA's terms. A report can carry several.

  • False Negative Result1

Patient problems as coded

Last 12 months. FDA's terms. A report can carry several.

  • No Clinical Signs, Symptoms or Conditions1

Recent recalls

From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.

  • Luminex Molecular Diagnostics Inc

    Z-0043-2025 · Started Sep 5, 2024 · Posted by FDA Oct 9, 2024

    Reason given: Respiratory pathogen panel may report an elevated rate (7.6% predicted probability of occurrence) of non-specific hMPV target (human Metapneumovirus) results, risk identified predominantly in clinical samples that present positivity for another target, leading to an erroneous co-infection result, can potentially...

    Cause as FDA categorized it: Device Design

10 more recall records with a free account

Back to all tools

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.